Sugi Predict

Sugi Predict / Compounds / SCHEMBL2951009

SCHEMBL2951009

SCHEMBL2951009

NC(=O)c1cccc(-c2cnc3ccc(NCc4cccc(Cl)c4)nn23)c1

nearest known ligand 0.74

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 14/20 0.74
▸ IKBKB O14920 1/20 0.59
▸ MAPK10 P53779 1/20 0.59
▸ NTRK1 P04629 2/20 0.56
▸ NTRK3 Q16288 2/20 0.56
▸ NTRK2 Q16620 2/20 0.56
▸ DYRK3 O43781 1/20 0.54
▸ DYRK1A Q13627 1/20 0.54
▸ DYRK2 Q92630 1/20 0.54
▸ DYRK1B Q9Y463 1/20 0.54
▸ PIM1 P11309 2/20 0.53
▸ PIM2 Q9P1W9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946441 0.86 FYN (0.83) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL2951889 0.85 FYN (0.63) FYNNTRK1NTRK3NTRK2PIM1
SCHEMBL18613320 0.85 FYN (1.00) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL2945069 0.85 FYN (0.81) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL30521744 0.85 FYN (1.00) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL2950407 0.84 FYN (0.77) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL30521811 0.83 FYN (1.00) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL18613504 0.83 FYN (1.00) FYNIKBKBMAPK10NTRK1NTRK3
SCHEMBL2945189 0.83 FYN (0.84) FYNPIM1PIM2
SCHEMBL2943531 0.82 FYN (0.76) FYNIKBKBMAPK10NTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885IKBKB 207/4885MAPK10 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.